Search Result




Gastroenteritis Virus Combo 6 (Norovirus I, II, Astrovirus, Rotavirus, Adenovirus, Sapovirus), Qualitative PCR (GVCOM6)

The test is intended to qualitatively detect norovirus 1, 2, astrovirus, rotavirus, adenovirus and sapovirus nuclecic acid in stool specimens. The multiplex realtime PCR targets and amplify the specific genes in the above viruses respectively and report with different coloured florescence signals at the same time.


Gastroenteritis Virus EPA Combo (Enterovirus, Parechovirus, Adenovirus), Qualitative PCR (GEPA)

The test is intended to qualitatively detect enterovirus, parechovirus and adenovirus nuclecic acid in stool specimens. The multiplex realtime PCR targets and amplify the specific genes in the above viruses respectively and report with different coloured florescence signals at the same time.


Gastroenteritis Bacteria Combo 2 (Salmonella spp, Shigella spp.), Qualitative PCR (GBCOM2)

The test is intended to qualitatively detect Salmonella and Shigella DNA in stool specimens. The multiplex realtime PCR targets and amplify the specific genes in the above bacteria respectively and report with different colured florescence signals at the same time.


Gastroenteritis Bacteria Combo 6 (Salmonella spp, Shigella spp., Yersinia enterocolitica, Clostridium difficile, Campylobacter coli/ jejuni/ lari, VTEC), Qualitative PCR (GBCOM6)

The test is intended to qualitatively detect for bacterial nucleic acid including Campylobacter coli/jejuni/lari, Clostridium difficile, Escherichia coli verotoxin positives, Salmonella spp., Shigella spp., enteroinvasive Escherichia coli and Yersinia enterocolitica in stool specimens. The multiplex realtime PCR targets and amplify the specific genes in the above bacteria species respectively and report with different coloured florescence signals at the same time.


Respiratory Infection Combo 21 (Influenza A, A(H1N1), B, Rhinovirus, Coronavirus NL63, 229E, OC43, HKU1, Parainfluenza1, 2, 3, 4, MPV A/B , Bocavirus, RSV A/B, Adenovirus, Enterovirus, Parechovirus, Mycoplasma pneumoniae), Qualitative PCR (REC21)

The test is aimed to detect the most common respiratory infectious pathogens including influenza A, influenza A (H1N1) swl, influenza B; human coronaviruses NL63, 229E, OC43 and HKU1, human parainfluenza 1,2,3 and 4, human metapneumovirus A and B, human rhinovirus, respiratory syncytial viruses A and B, adenovirus, enterovirus, huamn parechovirus, human bocavirus and mycoplasma pneumonia. The multiplex realtime Polymerase Chain Reaction (PCR) is able to target and amplify the conservative DNA regions of respective pathogens and report with different florescence signals at the same time.


Respiratory Bacterial Infection combo 7 (Streptococus pneumoniae, Haemophilius influenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella spp.), Qualitative PCR (RBC7)

The test is aimed to detect the bacterial pneumonia related pathogens includng Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, Legionella spec., Mycoplasma pneumoniae, Chlamydia pneumoniae. The multiplex realtime Polymerase Chain Reaction (PCR) is able to target and amplify the conservative DNA regions of respective pathogens and report with different coloured florescence signals at the same time.


HCV Genotype 1a, 1b, 2, 3, 4, 6 Identification, Qualitative PCR (*HCVG)



HCV RNA, Quantitative PCR (HCVQ)

Hepatitis C virus (HCV) detection and quantification is based on the amplification of a specific conservative DNA sequence and on measuring the amplification product concentration in the course of the PCR process by means of fluorescence marked probe.


Drug Resistance HBV genotyping (Lamivudine, Telbivudine, Adefovir, Entecavir Resistance Genotypes) , Qualitative PCR (*HYMDD)

Hepatitis B virus (HBV) with drug resistance (DR) mutation is detected with PCR followed by hybridization and visualization on a membrane strip. The multipex PCR amplification targets on 5 hot spots of drug resistance associated mutations, namely rtM250V, rtA181V, rtN236T, rtM204l and rtM204V. Different combinations of these mutation hot spots are associated with antiviral drug Lamivudine, Telbivudine, Adefovir and Entecavir resistance.


HBV DNA, Quantitative PCR (HBVQ)

Hepatitis B virus (HBV) detection and quantification is based on the amplification of a specific conservative DNA sequence and on measuring the amplification product concentration in the course of the PCR process by means of fluorescence marked probe.


Drug Resistance HBV genotyping (Lamivudine, Telbivudine, Adefovir, Entecavir Resistance Genotypes), Qualitative PCR, add-on with HBVQ (*HYMDD+)

Hepatitis B virus (HBV) with drug resistance (DR) mutation is detected with PCR followed by hybridization and visualization on a membrane strip. The multipex PCR amplification targets on 5 hot spots of drug resistance associated mutations, namely rtM250V, rtA181V, rtN236T, rtM204l and rtM204V. Different combinations of these mutation hot spots are associated with antiviral drug Lamivudine, Telbivudine, Adefovir and Entecavir resistance.


Influenza Combo 3 (Influenza A, B, H1N1), Qualitative PCR (RIC3)

This test is intended to qualitatively detect influenza A virus (FLUA), influenza B virus (FLUB) and swine-lineage influenza A virus (H1N1) nucleic acid in respiratory tract specimens. The multiplex realtime Polymerase Chain Reaction (PCR) targets and amplify the sub-type specific genes in FLUA, H1N1 and FLUB respectively and report with different coloured florescence signals at the same time.


Human Influenza A Virus, Qualitative PCR (RIA)

This test is intended to detect influenza A virus RNA in respiratory tract specimens by using real-time PCR hybridization-fluorescence detection.


Human Influenza B Virus, Qualitative PCR (RIB)

This test is intended to detect influenza B virus RNA in respiratory tract specimens by using real-time PCR hybridization-fluorescence detection.


Influenza A Virus Differentiation (H1N1, H3, H5, H7), Qualitative PCR, add-on with RIC2, RVC, RIA (RIAH+)

not necessarily to show as separated test item introduction on web-site


Gastroenteritis Virus Combo 3 (Norovirus I, II, Rotavirus), Qualitative PCR (GVCOM3)

The test is intended to qualitatively detect norovirus 1, 2 and rotavirus nuclecic acid in stool specimens. The multiplex realtime PCR targets and amplify the specific genes in the above viruses respectively and report with different coloured florescence signals at the same time.


Influenza A (H1N1) swl, Qualitative PCR (RH1N1)

This test is intended to detect swine-lineage influenza A virus (H1N1) nucleic acid in respiratory tract specimens by using real-time PCR hybridization-fluorescence detection.


Influenza Combo 2 (Influenza A, B), Qualitative PCR (RIC2)

This test is intended to qualitatively detect influenza A virus (FLUA) and influenza B virus (FLUB) nucleic acid in respiratory tract specimens. The multiplex PCR targets and amplify the conservative regions of specific genes in FLUA and FLUB respectively and report with different coloured florescence signals at the same time.


Respiratory Virus infection Combo 3 (Influenza A, B, RSV A/B), Qualitative PCR (RVC)

This test is intended to qualitatively detect influenza A virus (FLUA), Influenza B virus  (FLUB) and RSVA/B nucleic acid in respiratory tract specimens. The multiplex PCR targets and amplify the conservative regions of specific genes in FLUA, FLUB an+G18+G26


Influenza A Virus Differentiation (H1N1, H3, H5, H7), Qualitative PCR (RIAH)

This test is intended to identify the subtypes of influenza A virus in respiratory tract specimens. The multiplex realtime PCR targets and amplify the specific genes for influenza A virus subtypes respectively and report with different coloured florescence signals at the same time.


STD Combo 3 (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitallum), Qualitative PCR (SCOM3)

The test dectects Neisseria gonorrhoeae, Chlamydia trachomatis and Mycoplasma genitalium DNA by multiplex realtime PCR which targets and amplify the conservative DNA regions of respective pathogens and report with different coloured florescence signals at the same time


STD Combo 2 (Mycoplasma genitallum, Trichomonas vaginalis) , Qualitative PCR (SCO2T)

The test dectects Trichomonas vaginalis and Mycoplasma genitalium DNA by multiplex realtime PCR which targets and amplify the conservative DNA regions of respective pathogens and report with different coloured florescence signals at the same time


STD Combo 4 (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitallum, Trichomonas vaginalis), Qualitative PCR (SCOM4)

The test dectects Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and Mycoplasma genitalium DNA by multiplex realtime PCR which targets and amplify the conservative DNA regions of respective pathogens and report with coloured different florescence signals at the same time


STD Combo 9 (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitallum, Trichomonas vaginalis, Ureaplasma urealyticum/parvum, Gardnerella vaginalis, HSV1/2), Qualitative PCR (SCOM9)

The test detects Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, Gardnerella vaginalis, Ureaplasma urealyticum/parvum and Herpes Simplex Virus 1/2 DNA by multiplex realtime PCR, which target and amplify the conservative DNA regions of respective pathogens and report with different coloured florescence signals at the same time.


STD Combo10 (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitallum, Trichomonas vaginalis, Ureaplasma urealyticum, Ureaplasma parvum, Mycoplasma hominis, HSV1, HSV2, Treponema pallidum), Qualitative PCR (SCOM10)

The test detects Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma  parvum, Treponema pallidum, Herpes Simplex Virus 1 and 2 DNA by multiplex realtime Polymerase Chain Reactions (PCR), which target and amplify the conservative DNA regions of respective pathogens and report with different coloured florescence signals at the same time. The detection limit of each pathgen is as low as 1 copy/ul in this assay as provided by the manufacturer.


Gardnerella vaginalis (GV), Qualitative PCR (SGV)

Gardnerella vaginalis DNA detection is based on the realtime PCR which amplify and detect conserved DNA sequences that specific for G. vaginalis.


Mycoplasma hominis (MH), Qualitative PCR (SMH)

Mycoplasma hominis DNA detection is based on the realtime PCR which amplify and detect conserved DNA sequences that specific for M. hominis.


Treponema pallidum (TP), Qualitative PCR (STP)

Treponema pallidum DNA detection is based on the realtime PCR which amplify and detect conserved DNA sequences that specific for T. pallidum.


Candida albicans, Qualitative PCR (SCA)

Candida albicans DNA detection is based on the realtime PCR which amplify and detect conserved DNA sequences that specific for C. albicans.


Group B Streptococcus (S.agalactiae), Qualitative PCR (SGBS)

This test is intended to detect Group B Streptococcus Streptococcus agalactiae in blood by using real-time PCR hybridization-fluorescence detection.


Human Immunodeficiency Virus (HIV) type 1, Quantitative PCR (SHIV1Q)

This test is aimed to detect Human Immunodeficiency Virus type 1 (HIV-1) RNA by the real-time PCR. The HIV-1 detection is based on the duplex detection of a specific conservative region for all variants of the HIV-1 virus from the M group (including groups N and O) and for the virus CRF variants which maximize sensitivity and specificity for such detection. The detection is performed by the Reverse Transcription Polymerase Chain Reaction (RT-PCR) and the measuring of the amplification product concentration growth using fluorescence labelled probes.


High-risk HPV Screening (Detection of 14 Genotypes:16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and Identification of Genotype 16, 18, 33, 52, 58, Qualitative PCR (*SHPV)

Human Papilloma Virus (HPV) DNA is detected with PCR (polymerase chain reaction) followed by hybridization and visualization on a membrane strip while the clinical specimen types accepted for this test are dry swab and liquid-based method. The multiplex PCR detects 14 high-risk (HR) HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) whereas the 5 most frequently (76~80%) found genotypes 16, 18, 33, 52 and 58 in cervical cancers in Asians are further descriminated individually.


Human Papilloma Virus (HPV) Genotyping (29 Genotypes:High-risk:16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82 Low-risk: 6, 11, 40, 42, 43, 44, Others: 54, 55, 57, 67 and 69), Qualitative PCR + Biochip (*SHPVG)

Amplification of HPV genotype specific DNA sequences by PCR and followed by Biochip technology is used to detect and identify the specific HPV genotype(s) in this test.The HPV DNA genotyping test method identifies the presence of any of the 29 common HPV genotypes in the specimen. The low-risk HPV types identification include HPV 6, 11, 40, 42, 43, 44, 54, 55, 57, 67 and 69; whereas the high-risk HPV types identification include HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82. It covers approximately 97.3% of all HPV infection in the general population.


Epstein-Barr Virus (EBV), Quantitative PCR (OEBV)

Epstein-Barr virus (EBV) detection and quantification is based on the amplification of a specific conservative DNA sequence of EBV and on measuring the amplification product concentration in the course of the PCR process by means of fluorescence marked probe.


Vericella zoster virus (VZV), Qualitative PCR (OVZV)

Vericella zoster virus (VZV) DNA detection is based on the realtime PCR which amplify and detect conserved DNA sequences that specific for VZV.


Cytomegalovirus (CMV), Quantitative PCR (OCMV)

Cytomegalovirus (CMV) DNA detection is based on the realtime PCR which amplify and detect conserved DNA sequences that specific for CMV.


Breast / Ovarian Cancer Screening - BRCA1&2 Mutation (CBR12M)

Sanga Sequencing is applied for this test to find out if there is any mutation which is previously reproted pathogenic could be found in the specimen submitted.


Breast / Ovarian Cancer Screening - BRCA1 Copy Number Variations (CNV) (CBR1V)

Copy Number Variations (CNV) of breast and ovarian cancer related gene BRCA1 (NM_007294.3) were detect by Multiplex Ligation-dependent Probe Amplification (MLPA). This state-of-art technology is a semi-quantitative technique that is used to determine the relative copy number of target genes up to 60 DNA sequences in a single multiplex PCR-based reaction. In this test, 48 MLPA probes were included in the assay to target 24 exons of BRCA1. At least one MLPA probe is present for each exon in the major BRCA1 while eight probes are present for exon 11 (3426 nt long); three probes are present for exon 13, which is frequently deleted or duplicated (Hogervorst et al. 2003); three probes are present for exon 24 and two probes for exon 16; one probe is included for exon 1b, which is the first exon in transcript variants 3 and 5; and two probes detect sequences located 4.6 kb and 0.7 kb upstream of the BRCA1 gene. In addition, quality control probes, internal control probes and gender confirmation probes are also included in this assay to provide reliable, high quality and accurate results.


Breast / Ovarian / Prostate Cancer Cancer Screening - BRCA2 Copy Number Variations (CNV) (CBR2V)

Copy Number Variations (CNV) of breast, ovarian and prostate cancer related gene BRCA2 (NM_000059.3) and CHEK2 (NM_007194.3) are detected by Multiplex Ligation-dependent Probe Amplification (MLPA). This state-of-art technology is a semi-quantitative technique that is used to determine the relative copy number of target genes up to 60 DNA sequences in a single multiplex PCR-based reaction. In this test, 44 MLPA probes are included in the assay to target 27 exons of BRCA2 and CHEK2. At least one MLPA probe is present for each exon of BRCA2 gene while two probes are presenting for exons 1, 3 and 27, also for the large exon 11; in addition, two probes are present for sequences just before and after the BRCA2 gene. Furthermore, three probes for the CHEK2 gene on 22q12.1 are included. One of these probes will only result in an amplification product in case the DNA sample contains the CHEK2 1100delC mutation. The 1100delC allele appears to result in an increased risk for breast cancer and prostate cancer. Nevertheless, quality control probes, internal control probes and gender confirmation probes are also included in this assay to provide reliable, high quality and accurate results.


Prostate Cancer Screening - BRCA2 Mutation (CBR2M)

Sanga Sequencing is applied for this test to find out if there is any mutation which is previously reproted pathogenic could be found in the specimen submitted.


2 persons (PT2N)

The parentage analysis is based on multiplex PCR of Short Tandem Repeats (STR) at specific loci of DNA. A paternity index (PI) is calculated for each STR marker thus the product of the individual Pls is the combined Paternity Index (CPI) is finally used to calculate the probability of parentage. This 27-STR-marker parentage analysis fulfills the requirements from both USCIS (CODIS markers) and the new European Standard Set (ESS). And reaches the average exclusion chance much lower than required.


3 persons (PT3N)

The parentage analysis is based on multiplex PCR of Short Tandem Repeats (STR) at specific loci of DNA. A paternity index (PI) is calculated for each STR marker thus the product of the individual Pls is the combined Paternity Index (CPI) is finally used to calculate the probability of parentage. This 27-STR-marker parentage analysis fulfills the requirements from both USCIS (CODIS markers) and the new European Standard Set (ESS). And reaches the average exclusion chance much lower than required.


4 persons (PT4N)

The parentage analysis is based on multiplex PCR of Short Tandem Repeats (STR) at specific loci of DNA. A paternity index (PI) is calculated for each STR marker thus the product of the individual Pls is the combined Paternity Index (CPI) is finally used to calculate the probability of parentage. This 27-STR-marker parentage analysis fulfills the requirements from both USCIS (CODIS markers) and the new European Standard Set (ESS). And reaches the average exclusion chance much lower than required.


5 persons (PT5N)

The parentage analysis is based on multiplex PCR of Short Tandem Repeats (STR) at specific loci of DNA. A paternity index (PI) is calculated for each STR marker thus the product of the individual Pls is the combined Paternity Index (CPI) is finally used to calculate the probability of parentage. This 27-STR-marker parentage analysis fulfills the requirements from both USCIS (CODIS markers) and the new European Standard Set (ESS). And reaches the average exclusion chance much lower than required.


Each Additional person (PTACN)

The parentage analysis is based on multiplex PCR of Short Tandem Repeats (STR) at specific loci of DNA. A paternity index (PI) is calculated for each STR marker thus the product of the individual Pls is the combined Paternity Index (CPI) is finally used to calculate the probability of parentage. This 27-STR-marker parentage analysis fulfills the requirements from both USCIS (CODIS markers) and the new European Standard Set (ESS). And reaches the average exclusion chance much lower than required.


Hereditory Nonpolyposis Colorectral Cancer (HNPCC) Screening - MLH1&MSH2 Mutation (CMMRM)

Sanga Sequencing is applied for this test to find out if there is any mutation which is previously reproted pathogenic could be found in the specimen submitted.


Hereditory Nonpolyposis Colorectral Cancer (HNPCC) Screening - MLH1&MSH2 Copy Number Variations (CNV) (CMMRV)

Copy Number Variations (CNV) of HNPCC related genes namely MLH1 (NM_000249.3, chr.3p22.2), MSH2 (NM_000251.2, chr.2p21) and EPCAM (NM_002354.2, chr2p21) were detect by Multiplex Ligation-dependent Probe Amplification (MLPA). This state-of-art technology is a semi-quantitative technique that is used to determine the relative copy number of target genes up to 60 DNA sequences in a single multiplex PCR-based reaction. In this test, 48 MLPA probes were included in the assay to target 19 exons of the MLH1, 16 exons of the MSH2 and the last exon of EPCAM (formerly known as TACSTD1); quality control probes, internal control probes and gender confirmation probes are also included to provide reliable, high quality and accurate results.


KRAS Oncogene Mutation Screening, 7 Somatic Mutations (CKR)

This test intended for the detection of 7 somatic mutations in the KRAS oncogene by realtime PCR and will provide a qualitative assessment of mutation status. This test acquire results from DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) colorectal tissue.


BRAF Mutation Screening, 5 Somatic Mutations (CBF)

This test is for the detection of five somatic mutations found in the BRAF gene and provides qualitative assessment of mutation status. DNA will be extracted from formalin fixed paraffin-embedded (FFPE) tumor tissue and tested using real-time PCR. The result might aid the clinician in identifying cancer patients who may benefit from BRAF targeted therapy, such as vemurafenib.


EGFR Cancer-Related Gene Screening, 3 Mutations (Plasma) (CER)

This test is for the detection of exon 19 deletions, exon 20 and 21 substitutions (T790M and L858R respectively) in the epidermal growth factor receptor (EGFR) gene and will provide a qualitative assessment of the mutation status. Results are intended to aid the clinician in identifying patients with NSCLC who may benefit from treatment with IRESSA (gefitinib), when a tissue sample cannot be evaluated.


JAK2 V617F/G1849T Mutation Screening (CJK)

This test is intended for the detection and quantification of JAK2 V617F/G1849T allele in genomic DNA extracted from peripheral blood of subjects with suspected myeloproliferative neoplasm (MPN) by realtime PCR. The absence of the JAK2 V617F/G1849T mutation does not exclude the presence of other JAK2 mutations. The test can report false Negative results in case of additional mutations located in nucleotides 88504 to 88622. The JAK2 V617F mutation is detected in >95% of patients with polycythemia vera (PV), 50–60% of patients with essential thrombocythemia (ET), and in 50% of patients with primary myelofibrosis (PMF). JAK2 V617F has been also detected in some rare cases of chronic myelomonocytic leukemia, myelodysplasic syndrome, systemic mastocytosis, and chronic neutrophilic leukemia, but in 0% of CML.Traditionally, the diagnosis of MPNs was based on clinical, bone marrow histology and cytogenetic criteria. The discovery of a disease-specific molecular marker resulted in both simplification of the process and increased diagnostic accuracy. Detection of the JAK2 V617F mutation is now part of the reference WHO 2008 criteria for the diagnosis of BCR-ABL negative MPN (Table 1), and presence of this mutation is a major criterion for diagnostic confirmation.


BCR-ABL Fusion Gene Screening (CBL)

This test is intended to monitor deep molecular response in patients diagnosed with chronic phase Philadelphia chromosome positive (Ph+) p210 chronic myeloid leukemia (CML) by realtime PCR. It is calibrated against the World Health Organization (WHO) International Genetic Reference Panel. This assay exploits the qPCR double-dye oligonucleotide hydrolysis principle.


PML-RARA Fusion Gene Screening (CPL)

The test is intended for the quantification of PML-RARA type bcr1 fusion transcripts in bone marrow or peripheral blood samples in a subgroup of acute myeloid leukemia (AML) patients diagnosed with M3 cytomorphology and t(15;17)(q22;q21) translocation, with a breakpoint into PML intron 6 by realtime PCR. The results obtained are intended to be used as an aid to monitor efficacy of treatment in patients undergoing therapy, and for minimal residual disease (MRD) follow-up to monitor disease relapse.


Zika Virus, Qualitative PCR (OZKV)

Realtime PCR by CE-IVD assay kit


HCV Genotype 1a, 1b, 2, 3, 4, 6 Identification, Qualitative PCR (Add-on with HCVQ) (*HCVG +)

HCV genotypes including 1a, 1b, 2, 3, 4, and 6 are detected with PCR (polymerase chain reaction) followed by hybridization and visualization on a membrane strip. 


ProGene Talent Gene & Career Analysis (TAL01)

Cell Sample is scraped from buccal mucosa (surface of the gum and cheek) using a cotton swab.
The sample will be analysed anonymously by the latest technology in certified laboratories from the United States. 


ProGene Nutrifitness (FIT01)

The sample will be analysed anonymously by the latest technology in certified laboratories from the Europe.


ProGene Disease 100 (DIS01)

Cell Sample is scraped from buccal mucosa (surface of the gum and cheek) using a cotton swab.
The sample will be analysed anonymously by the latest technology in certified laboratories from the United States. 


Zika, Dengue and Chikungunya virus identification, multiplex qualitative PCR (OZDC )

Realtime PCR by CE-IVD assay kit


ProGene Onco (DTON)

Buccal swab sample from your inner cheek  and send it to our laboratory.


ProGene PGx (DTPG)

Buccal swab sample from your inner cheek and send it to our laboratory.


ProGene Wellness (DTWEL)

Buccal swab sample from your inner cheek and send it to our laboratory.


ProGene Child (DTCH)

Buccal swab sample from your inner cheek and send it to our laboratory.


ProGene Cardio & Metabolic (DTCA)

Buccal swab sample from your inner cheek or a blood sample and send it to our laboratory.


Cancer Genomic Profiling (ACON+ )

N/A


Tumour Burden Monitor (ACMON / ACMON+)


ProGene EverBright (VBEAU)

Buccal swab sample from your inner cheek and send it to our laboratory.


ProGene Weight Management (VFIT)

Buccal swab sample from your inner cheek and send it to our laboratory.


ProGene NeverAge (VSKIN)

Buccal swab sample from your inner cheek or a blood sample and send it to our laboratory.